A Phase 1 interventional study of Axitinib + Paclitaxel + Carboplatin (Cohort 1) and Axitinib + Paclitaxel + Carboplatin (Cohort 2) in Neoplasms, sponsored by Pfizer. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-04.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 102 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following separate groups were included: axitinib 1. plus carboplatin/paclitaxel in three different schedules 2. plus paclitaxel 3. plus docetaxel/carboplatin 4. plus docetaxel 5. plus capecitabine 6. plus gemcitabine/cisplatin 7. plus pemetrexed/cisplatin
Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1) · Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2) · Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3) · Drug: Axitinib + Paclitaxel (Cohort 4) · Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a) · Drug: Axitinib + Docetaxel (Cohort 5) · Drug: Axitinib + Capecitabine (Cohort 6) · Drug: Axitinib + Capecitabine (Cohort 7) · Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8) · Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Drug pages: Axitinib · Paclitaxel · Carboplatin
Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
Drug pages: Axitinib · Paclitaxel · Carboplatin
Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Drug pages: Axitinib · Paclitaxel · Carboplatin
Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Drug pages: Axitinib · Paclitaxel
Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
Drug pages: Axitinib · Docetaxel · Carboplatin
Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Drug pages: Axitinib · Docetaxel
Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
Drug pages: Axitinib · Capecitabine
Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Drug pages: Axitinib · Capecitabine
Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Drug pages: Axitinib · Gemcitabine · Cisplatin
Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
Drug pages: Axitinib · Pemetrexed · Cisplatin
Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy
MTD defined as the dose level at which more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 nonhematological toxicities or \>=0.5 teaspoon/day hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
Time frame: Baseline to withdrawal from study or Day 21 of Cycle 1 [all cohorts except cohort 4 (Day 28 of Cycle 1)]
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Minimum Observed Plasma Trough Concentration (Cmin) for Axitinib (AG-013736)
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Maximum Observed Plasma Concentration (Cmax) for Paclitaxel
Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Minimum Observed Plasma Trough Concentration (Cmin) for Paclitaxel
Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Plasma Clearance (CL) for Paclitaxel
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Plasma Decay Half Life (t1/2) for Paclitaxel
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Maximum Observed Plasma Concentration (Cmax) for Docetaxel
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Minimum Observed Plasma Trough Concentration (Cmin) for Docetaxel
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Plasma Clearance (CL) for Docetaxel
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Plasma Decay Half Life (t1/2) for Docetaxel
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Maximum Observed Plasma Concentration (Cmax) for Capecitabine
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Minimum Observed Plasma Trough Concentration (Cmin) for Capecitabine
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Apparent Oral Clearance (CL/F) for Capecitabine
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Plasma Decay Half Life (t1/2) for Capecitabine
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Maximum Observed Plasma Concentration (Cmax) for Gemcitabine
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Minimum Observed Plasma Trough Concentration (Cmin) for Gemcitabine
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Plasma Clearance (CL) for Gemcitabine
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Plasma Decay Half Life (t1/2) for Gemcitabine
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Maximum Observed Plasma Concentration (Cmax) for Carboplatin
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Minimum Observed Plasma Trough Concentration (Cmin) for Carboplatin
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Plasma Clearance (CL) for Carboplatin
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Plasma Decay Half Life (t1/2) for Carboplatin
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin
AUC (0-8) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 8 hours (0-8).
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Maximum Observed Plasma Concentration (Cmax) for Cisplatin
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Minimum Observed Plasma Trough Concentration (Cmin) for Cisplatin
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Plasma Clearance (CL) for Cisplatin
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Plasma Decay Half Life (t1/2) for Cisplatin
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Maximum Observed Plasma Concentration (Cmax) for Pemetrexed
Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Minimum Observed Plasma Trough Concentration (Cmin) for Pemetrexed
Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Plasma Clearance (CL) for Pemetrexed
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Plasma Decay Half Life (t1/2) for Pemetrexed
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Percentage of Participants With Objective Response
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline and thereafter every 2 cycles up to disease progression or discontinuation from study or up to 155 weeks
| Milestone | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 5 | 20 | 7 | 1 | 7 | 9 | 19 | 21 | 6 |
| Completed | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not completed | 3 | 4 | 19 | 6 | 1 | 7 | 9 | 19 | 20 | 5 |
| Withdrew: Lack of efficacy | 2 | 2 | 10 | 3 | 0 | 4 | 5 | 13 | 10 | 2 |
| Withdrew: Adverse event | 0 | 1 | 3 | 0 | 1 | 2 | 3 | 4 | 6 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 5 | 3 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 |
MTD defined as the dose level at which more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 nonhematological toxicities or \>=0.5 teaspoon/day hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
| mg BID | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy | 5 | 5 | 5 | 5 | NA | 5 | 5 | 5 | 5 |
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
| nanogram*hour/milliliter (ng*hr/mL) | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736) | 61.58 ± 54.66 | 242.41 ± 132.24 | 475.18 ± 380.13 | 154.43 ± 28.93 | 780.99 ± 535.30 | 365.95 ± 143.13 | 449.99 ± 323.59 | 416.30 ± 450.43 | 420.64 ± 200.32 |
| ng/mL | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736) | 5.97 ± 2.59 | 23.36 ± 8.08 | 42.58 ± 18.25 | 44.58 ± 44.78 | 67.96 ± 39.24 | 37.51 ± 15.31 | 43.97 ± 28.82 | 40.97 ± 33.06 | 31.53 ± 22.87 |
No measurements were reported for this outcome.
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.
| Liter/hour (L/hr) | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) for Axitinib (AG-013736) | 49.39 ± 34.46 | 40.72 ± 46.75 | 29.73 ± 18.49 | 65.69 ± 11.94 | 14.35 ± 7.67 | 26.64 ± 15.58 | 83.46 ± 171.05 | 50.05 ± 56.75 | 25.10 ± 21.31 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Plasma Decay Half Life (t1/2) for Axitinib (AG-013736) | 2.75 ± 2.06 | 2.90 ± 1.78 | 2.80 ± 1.04 | 1.45 ± 0.27 | 4.07 ± 2.60 | 3.85 ± 1.93 | 3.64 ± 2.03 | 2.68 ± 1.09 | 5.02 ± 3.38 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel | 5683.55 ± 1519.49 | 19959.91 ± 5951.86 |
| ng/mL | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Paclitaxel | 3698.33 ± 1198.32 | 6105.00 ± 2167.59 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|---|
| Plasma Clearance (CL) for Paclitaxel | 30.48 ± 6.16 | 21.61 ± 9.38 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|---|
| Plasma Decay Half Life (t1/2) for Paclitaxel | 12.51 ± 1.03 | 8.36 ± 2.16 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Axitinib + Docetaxel (Cohort 5) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel | 3478.49 ± 870.12 |
| ng/mL | Axitinib + Docetaxel (Cohort 5) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Docetaxel | 3130.00 ± 1106.23 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Docetaxel (Cohort 5) |
|---|---|
| Plasma Clearance (CL) for Docetaxel | 42.96 ± 6.04 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Docetaxel (Cohort 5) |
|---|---|
| Plasma Decay Half Life (t1/2) for Docetaxel | 11.49 ± 0.97 |
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).
| ng*hr/mL | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) |
|---|---|---|
| Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine | 20534.52 ± 3797.63 | 22163.88 ± 16881.96 |
| ng/mL | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Capecitabine | 10808.00 ± 6173.62 | 10588.38 ± 9954.76 |
No measurements were reported for this outcome.
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.
| Liter/hr | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) |
|---|---|---|
| Apparent Oral Clearance (CL/F) for Capecitabine | 209.05 ± 24.29 | 314.12 ± 247.27 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) |
|---|---|---|
| Plasma Decay Half Life (t1/2) for Capecitabine | 0.85 ± 0.90 | 1.44 ± 3.05 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Axitinib + Gemcitabine + Cisplatin (Cohort 8) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine | 10991.16 ± 3099.28 |
| ng/mL | Axitinib + Gemcitabine + Cisplatin (Cohort 8) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Gemcitabine | 20635.29 ± 10656.86 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Gemcitabine + Cisplatin (Cohort 8) |
|---|---|
| Plasma Clearance (CL) for Gemcitabine | 224.36 ± 74.45 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Gemcitabine + Cisplatin (Cohort 8) |
|---|---|
| Plasma Decay Half Life (t1/2) for Gemcitabine | 0.29 ± 0.07 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin | 55580.26 ± 9689.44 |
| ng/mL | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Carboplatin | 23383.33 ± 7170.75 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|
| Plasma Clearance (CL) for Carboplatin | 12.57 ± 3.99 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3) |
|---|---|
| Plasma Decay Half Life (t1/2) for Carboplatin | 2.62 ± 0.55 |
AUC (0-8) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 8 hours (0-8).
| ng*hr/mL | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|
| Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin | 2932.43 ± 929.69 | 2703.92 ± 688.68 |
| ng/mL | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Cisplatin | 1680.54 ± 628.63 | 1176.00 ± 295.29 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|
| Plasma Clearance (CL) for Cisplatin | 46.31 ± 14.57 | 46.80 ± 14.92 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|
| Plasma Decay Half Life (t1/2) for Cisplatin | 2.61 ± 1.27 | 3.91 ± 1.59 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed | 133032.97 ± 40176.65 |
| ng/mL | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Pemetrexed | 83925.00 ± 35820.05 |
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.
| L/hr | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|
| Plasma Clearance (CL) for Pemetrexed | 7.26 ± 2.08 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hr | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|
| Plasma Decay Half Life (t1/2) for Pemetrexed | 2.77 ± 1.80 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Percentage of Participants | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response | 100.0 | 0 | 35.0 | 66.7 | 50.0 | 11.1 | 11.8 | 23.8 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Paclitaxel + Carboplatin (Cohort 1) | — | 2/3 (66.7%) | 3/3 (100%) |
| Axitinib + Paclitaxel + Carboplatin (Cohort 2) | — | 2/5 (40%) | 5/5 (100%) |
| Axitinib + Paclitaxel + Carboplatin (Cohort 3) | — | 11/20 (55%) | 20/20 (100%) |
| Axitinib + Paclitaxel (Cohort 4) | — | 2/7 (28.6%) | 7/7 (100%) |
| Axitinib + Docetaxel + Carboplatin (Cohort 4a) | — | 1/1 (100%) | 1/1 (100%) |
| Axitinib + Docetaxel (Cohort 5) | — | 4/7 (57.1%) | 7/7 (100%) |
| Axitinib + Capecitabine (Cohort 6) | — | 6/9 (66.7%) | 9/9 (100%) |
| Axitinib + Capecitabine (Cohort 7) | — | 9/19 (47.4%) | 19/19 (100%) |
| Axitinib + Gemcitabine + Cisplatin (Cohort 8) | — | 13/21 (61.9%) | 21/21 (100%) |
| Axitinib + Pemetrexed + Cisplatin (Cohort 9) | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|---|
| GranulocytopeniaBlood and lymphatic system disorders | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 0/7 | 0/9 | 0/19 | 0/21 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 1/7 | 0/9 | 1/19 | 0/21 | 0/6 |
| NauseaGastrointestinal disorders | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 1/7 | 0/9 | 1/19 | 2/21 | 0/6 |
| VomitingGastrointestinal disorders | 0/3 | 0/5 | 1/20 | 0/7 | 1/1 | 0/7 | 0/9 | 1/19 | 1/21 | 0/6 |
| AstheniaGeneral disorders | 0/3 | 0/5 | 1/20 | 0/7 | 1/1 | 1/7 | 0/9 | 0/19 | 0/21 | 0/6 |
| FatigueGeneral disorders | 0/3 | 1/5 | 0/20 | 0/7 | 1/1 | 1/7 | 0/9 | 1/19 | 1/21 | 0/6 |
| DiverticulitisInfections and infestations | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 0/7 | 0/9 | 0/19 | 0/21 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/5 | 1/20 | 1/7 | 1/1 | 1/7 | 1/9 | 1/19 | 2/21 | 0/6 |
| Peripheral sensory neuropathyNervous system disorders | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 0/7 | 0/9 | 0/19 | 0/21 | 0/6 |
| Renal failure acuteRenal and urinary disorders | 0/3 | 0/5 | 0/20 | 0/7 | 1/1 | 0/7 | 0/9 | 1/19 | 1/21 | 0/6 |
| Event | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) |
|---|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/3 | 3/5 | 7/20 | 1/7 | 0/1 | 2/7 | 2/9 | 2/19 | 11/21 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/5 | 2/20 | 2/7 | 1/1 | 3/7 | 3/9 | 3/19 | 6/21 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 3/3 | 3/5 | 7/20 | 5/7 | 1/1 | 4/7 | 4/9 | 14/19 | 8/21 | 1/6 |
| NauseaGastrointestinal disorders | 3/3 | 5/5 | 5/20 | 5/7 | 0/1 | 4/7 | 5/9 | 12/19 | 15/21 | 2/6 |
| AstheniaGeneral disorders | 2/3 | 2/5 | 3/20 | 0/7 | 1/1 | 0/7 | 2/9 | 1/19 | 2/21 | 1/6 |
| FatigueGeneral disorders | 3/3 | 4/5 | 9/20 | 7/7 | 0/1 | 5/7 | 7/9 | 13/19 | 16/21 | 2/6 |
| Oedema peripheralGeneral disorders | 0/3 | 1/5 | 1/20 | 1/7 | 1/1 | 1/7 | 2/9 | 1/19 | 2/21 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 4/5 | 9/20 | 3/7 | 1/1 | 3/7 | 3/9 | 11/19 | 11/21 | 2/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/3 | 2/5 | 6/20 | 2/7 | 1/1 | 1/7 | 1/9 | 3/19 | 0/21 | 0/6 |
| DizzinessNervous system disorders | 2/3 | 2/5 | 3/20 | 2/7 | 1/1 | 1/7 | 2/9 | 4/19 | 6/21 | 0/6 |
| Age Continuous(years) | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 61 ± 11.4 | 62 ± 16.6 | 59.5 ± 10.6 | 60.7 ± 10.2 | 64 ± NA | 63.4 ± 11.9 | 60.4 ± 12.4 | 53.4 ± 10.6 | 54 ± 10.3 | 58.8 ± 9.0 | 57.8 ± 11.1 |
| Sex: Female, Male(Participants) | Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Axitinib + Paclitaxel (Cohort 4) | Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Axitinib + Docetaxel (Cohort 5) | Axitinib + Capecitabine (Cohort 6) | Axitinib + Capecitabine (Cohort 7) | Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Axitinib + Pemetrexed + Cisplatin (Cohort 9) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 3 | 1 | 5 | 5 | 11 | 12 | 3 | 47 |
| Male | 1 | 3 | 17 | 4 | 0 | 2 | 4 | 8 | 9 | 3 | 51 |
The record gives a start of Dec 2005, a primary completion of Aug 2009 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Axitinib · Paclitaxel · Carboplatin · Docetaxel · Capecitabine · Gemcitabine · Cisplatin · Pemetrexed